Zanzalintinib for colorectal cancer with residual tumor dna
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial is testing a new drug (zanzalintinib) alone or with pembrolizumab to see if it can stop cancer from coming back in people with colorectal cancer who have no visible cancer on scans but still have tumor DNA in their blood.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had stage II or III colon or rectal cancer (not stage IV).
- You have completed your main treatment (surgery, with or without chemo or radiation).
- A blood test shows that small bits of tumor DNA are still present in your blood ('molecular residual disease').
- Your latest CT or MRI scans show no visible cancer anywhere in the body.
- You have not had immunotherapy or VEGF inhibitor drugs before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called zanzalintinib for people with advanced liver cancer (HCC) that can't be treated with surgery. You may join if your cancer has gotten worse after at least one prior treatment, or you couldn't tolerate that treatment.
This trial tests a new drug called zanzalintinib for people with advanced bladder cancer that has worsened after previous treatments. The goal is to see if zanzalintinib can help control the cancer.
This study tests a new drug called zanzalintinib in men with advanced prostate cancer (metastatic castration-resistant prostate cancer) who have already received Pluvicto treatment. The goal is to see if this drug can help slow or stop cancer growth when other hormone therapies are no longer working.
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
This trial tests a new drug combination for people with advanced clear cell kidney cancer that has gotten worse after initial immunotherapy treatment. The goal is to see if adding zanzalintinib to another immunotherapy can help control the cancer.
This trial tests two new drugs, belzutifan and zanzalintinib, for people with advanced kidney cancer that returned after or within 2 years of finishing an immunotherapy treatment after surgery. You cannot have received any other cancer treatments besides that immunotherapy.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.